title: Effect of local administration of lymphokine-activated killer cells and interleukin-2 on malignant brain tumor patients.
abstract: Nine patients with malignant brain tumors were treated with intratumoral infusion of lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2). LAK cells were generated from macrophage-depleted peripheral blood lymphocytes by culturing with IL-2 for 4 days. The resulting LAK cells showed strong cytotoxic activity against tumor target cells. Three patients received sufficient LAK cells (> or = 5.76 x 10(8)) to show partial tumor response by computed tomography and clinical signs. No severe neurological side effects occurred in any patient. Intratumoral administration of LAK cells and IL-2 can be effective in patients with malignant brain tumors.
authors.affiliation: Department of Neurosurgery, Sapporo Medical College.
authors.forename: Y
authors.initials: Y
authors.lastname: Ibayashi
authors.forename: T
authors.initials: T
authors.lastname: Yamaki
authors.forename: T
authors.initials: T
authors.lastname: Kawahara
authors.forename: M
authors.initials: M
authors.lastname: Daibo
authors.forename: T
authors.initials: T
authors.lastname: Kubota
authors.forename: T
authors.initials: T
authors.lastname: Uede
authors.forename: S
authors.initials: S
authors.lastname: Tanabe
authors.forename: K
authors.initials: K
authors.lastname: Hashi
mesh_terms: D000328:Adult; D001921:Brain / Q000187:drug effects* / Q000276:immunology / Q000473:pathology* / Q000601:surgery; D001932:Brain Neoplasms / Q000145:classification / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D003399:Craniotomy; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D008264:Macrophages / Q000276:immunology; D008297:Male; D008875:Middle Aged; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D007376:Interleukin-2